This page is intended for medical professionals evaluating DDW for their patients. It contains a fuller technical and regulatory account than the patient-facing pages.
Mechanism of action — current understanding
The deuterium-depletion hypothesis centres on mitochondrial isotope effects in ATP synthase and other proton-translocating enzymes. Reduced cellular deuterium concentration is hypothesised to alter kinetic isotope effects favourably, with downstream effects on oxidative metabolism, redox status, and cell-cycle regulation in tumour cells. The hypothesis is supported by in-vitro and in-vivo data; mechanistic specifics remain an active area of investigation.
Clinical evidence summary
Phase 2 RCTs from Somlyai and colleagues in prostate, breast, and lung cancer have reported favourable trends in time-to-progression and quality-of-life endpoints. Sample sizes have been modest. Replication outside Hungary is limited. Indian clinical experience is currently observational and clinic-led.
Quality and characterisation
Deutra is manufactured by multi-stage fractional vacuum distillation. Every batch is characterised by isotope-ratio mass spectrometry; ppm is reported on the Certificate of Analysis (CoA) and matched to a batch ID. CoAs from the past 24 months are available on request to verifying physicians.
Drug-interaction data
No clinically significant interactions have been reported in the published literature, but the dataset is small. Please apply standard pharmacovigilance and document patient response.
Ordering for clinics
Clinics and hospitals can place purchase orders directly. Volume pricing, batch reservation, and bulk delivery are available. Contact: clinical@deutra.in.